NDA 021107 · Legacy
Lotronex
Alosetron Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Sep 8, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Feb 9, 2000
Approved uses
4
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
833
362 serious, 41 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS Infrequent but serious gastrointestinal adverse reactions have been reported with the use of LOTRONEX. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death. LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy [see Indications and Usage ( 1 )] . LOTRONEX should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their prescriber. LOTRONEX should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the...
What it is approved for
From the label in effect Jun 30, 2026.
LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. LOTRONEX is a selective serotonin 5-HT 3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. ( 1 ) Severe IBS includes diarrhea and 1 or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. ( 1 )
Mechanism: Alosetron is a potent and selective 5-HT 3 receptor antagonist. 5-HT 3 receptors are ligand-gated cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit, and gastrointestinal secretions, processes that relate to the pathophysiology of IBS. 5-HT 3 receptor antagonists such as alosetron inhibit activation of non-selective cation channels, which results in the modulation...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 1, 2008 Supplement 13 · Efficacy LetterLabel
- Jan 31, 2005 Supplement 9 · Efficacy
- Jun 7, 2002 Supplement 5 · Efficacy · priority review LetterLabelReview
- Feb 9, 2000 Original approval · Type 1 - New Molecular Entity · priority review NovelMedication GuideOther Important Information from FDAReview
2 products under this application
- LOTRONEX · ALOSETRON HYDROCHLORIDE EQ 0.5MG BASE · TABLET, ORAL · Prescription · TE AB
- LOTRONEX · ALOSETRON HYDROCHLORIDE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Alosetron" as an intervention, any sponsor and status, largest first.
- Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00067561 · 702 participants · Start Jun 2003 · Primary completion Jan 2005
Drug: Alosetron · For: Irritable Colon; Irritable Bowel Syndrome (IBS)
Sites: Birmingham, Alabama; Calera, Alabama; Tuscaloosa, Alabama · 178 sites in all
- Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00067457 · 700 participants · Start Jun 2003 · Primary completion Dec 2005
Drug: alosetron · For: Irritable Colon; Irritable Bowel Syndrome (IBS)
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 191 sites in all
GlaxoSmithKlineGSK (GSK)
NCT00370032 · 49 participants · Start Dec 2006 · Primary completion Dec 2007
Drug: alosetron · For: Irritable Colon
Sites: London, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT01855711 · 32 participants · Start Sep 18, 2003 · Primary completion May 10, 2005
Drug: GR68755 (Alosetron hydrochloride) 1 mg tablet · For: Irritable Colon
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- constipation128
- drug ineffective125
- abdominal pain107
- diarrhoea107
- colitis ischaemic65
- vomiting56
- nausea54
- adverse event43
- abdominal pain upper38
- gastrointestinal injury35
- rectal haemorrhage35
- pain27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 182 |
| 2005 | 89 |
| 2006 | 112 |
| 2007 | 49 |
| 2008 | 23 |
| 2009 | 17 |
| 2010 | 23 |
| 2011 | 17 |
| 2012 | 31 |
| 2013 | 17 |
| 2014 | 17 |
| 2015 | 31 |
| 2016 | 37 |
| 2017 | 58 |
| 2018 | 27 |
| 2019 | 12 |
| 2020 | 16 |
| 2021 | 20 |
| 2022 | 18 |
| 2023 | 10 |
| 2024 | 7 |
| 2025 | 15 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lotronex (Alosetron HCl)
2024 spending
$1.3M
Beneficiaries
39
226 claims
Per beneficiary
$33,343
$66.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,760,640 |
| 2021 | $1,348,787 |
| 2022 | $1,299,872 |
| 2023 | $1,324,334 |
| 2024 | $1,300,382 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Irritable bowel syndrome.
Ford AC, Vandvik PO · BMJ Clin Evid 2010 · Systematic Review
- Irritable bowel syndrome.
Ford AC, Vandvik PO · BMJ Clin Evid 2012 · Systematic Review
- Effect of alosetron on the pharmacokinetics of alprazolam.
D'Souza DL, Levasseur LM, Nezamis J, et al. · J Clin Pharmacol 2001 · Clinical Trial, Comparative Study
- Irritable bowel syndrome.
de Wit N, Rubin G, Jones RH · BMJ Clin Evid 2007 · Systematic Review
- Effect of alosetron on the pharmacokinetics of fluoxetine.
D'Souza DL, Dimmitt DC, Robbins DK, et al. · J Clin Pharmacol 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Shah E, Kim S, Chong K, et al. · Am J Med 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.